Effect of coronavirus disease 2019 on recurrences and follow up of head and neck squamous cell carcinoma
Autor: | Ilpo Kinnunen, E Kytö, E Haapio, Heikki Irjala |
---|---|
Rok vydání: | 2021 |
Předmět: |
Pediatrics
medicine.medical_specialty Delayed Diagnosis Coronavirus disease 2019 (COVID-19) Aftercare 03 medical and health sciences 0302 clinical medicine Recurrence Pandemic Epidemiology Medicine Humans In patient Prospective Studies 030223 otorhinolaryngology Prospective cohort study Finland Head And Neck Cancer business.industry Head and neck cancer Main Articles Follow-Up Care COVID-19 General Medicine medicine.disease Head and neck squamous-cell carcinoma Telemedicine Otorhinolaryngology Head and Neck Neoplasms 030220 oncology & carcinogenesis Carcinoma Squamous Cell Neoplasm Recurrence Local business After treatment |
Zdroj: | The Journal of Laryngology and Otology |
ISSN: | 1748-5460 0022-2151 |
Popis: | ObjectiveThis prospective study aimed to evaluate possible diagnostic delays in head and neck squamous cell carcinoma recurrences due to the changed follow-up protocol during the coronavirus disease 2019 pandemic.MethodsThe follow-up appointments of head and neck squamous cell carcinoma patients treated more than one year prior to the pandemic were changed to telephone appointments in order to reduce physical visits to the hospital. All contacts, reasons for contact and recurrent cancers were recorded.ResultsThere were 17 recurrences during a seven-month study period among 178 patients treated in the previous year (10 per cent); 14 of these recurrences occurred in patients whose treatment had ended less than one year previously and 3 occurred more than one year after treatment had ended. There was no delay in diagnoses of recurrent tumours or treatment despite reduced visits because of the coronavirus disease 2019 pandemic.ConclusionAccording to our analyses, no delay was caused in the diagnoses of recurrent diseases. Follow up by telephone or telemedicine can be considered as part of the follow-up protocol one year after the treatment of head and neck squamous cell carcinoma when necessary. |
Databáze: | OpenAIRE |
Externí odkaz: |